Clinuvel Pharmaceuticals Ltd CLVLY:OTCPK

*Data is delayed | Exchange | USD
Last | 03/28/24 EDT
9.46quote price arrow up+0.38 (+4.19%)
Volume
15,009
52 week range
8.54 - 13.97
Loading...
  • Open9.63
  • Day High9.63
  • Day Low9.46
  • Prev Close9.08
  • 52 Week High13.97
  • 52 Week High Date04/13/23
  • 52 Week Low8.54
  • 52 Week Low Date03/12/24

Key Stats

  • Market Cap480.22M
  • Shares Out50.13M
  • 10 Day Average Volume3,233
  • Dividend0.03
  • Dividend Yield0.34%
  • Beta1.25
  • YTD % Change-14.43

KEY STATS

  • Open9.63
  • Day High9.63
  • Day Low9.46
  • Prev Close9.08
  • 52 Week High13.97
  • 52 Week High Date04/13/23
  • 52 Week Low8.54
  • 52 Week Low Date03/12/24
  • Market Cap480.22M
  • Shares Out50.13M
  • 10 Day Average Volume3,233
  • Dividend0.03
  • Dividend Yield0.34%
  • Beta1.25
  • YTD % Change-14.43

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date09/07/2023
  • Div Amount0.0324
  • Split Date-
  • Split Factor-

Latest On Clinuvel Pharmaceuticals Ltd

 

Profile

MORE
Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a...
Jeffrey Rosenfeld OBE
Non-Executive Chairman of the Board
Philippe Wolgen M.D.
Chief Executive Officer, Managing Director, Executive Director
Darren Keamy CPA
Chief Financial Officer, Company Secretary
Address
Level 22, 535 Bourke Street
Melbourne, VIC
3000
Australia